A Prospective Open‐Label Observational Study of a Buffered Soluble 70 mg Alendronate Effervescent Tablet on Upper Gastrointestinal Safety and Medication Errors: The GastroPASS Study

ABSTRACT Upper gastrointestinal (GI) side effects are a main reason for discontinuing bisphosphonate treatment, an important therapeutic option for osteoporosis patients. Consequently, the development of novel formulations with improved tolerability is warranted. In this multicenter prospective, obs...

Full description

Bibliographic Details

Published in:	JBMR Plus
Main Authors:	Salvatore Minisola, Antonio P Vargas, Giulia Letizia Mauro, Fernando Bonet Madurga, Giovanni Adami, Dennis M Black, Nawab Qizilbash, Josep Blanch‐Rubió
Format:	Article
Language:	English
Published:	Oxford University Press 2021-07-01
Subjects:	ALENDRONATE EFFERVESCENT GASTROINTESTINAL ADVERSE EVENTS OSTEOPOROSIS POSTMENOPAUSAL WOMEN
Online Access:	https://doi.org/10.1002/jbm4.10510